Profil
Brian Heaphy has worked as a Director at MyoKardia, Inc. since 2020 and has been working at Davis Polk & Wardwell LLP since 2004.
Postes actifs de Brian Heaphy
| Sociétés | Poste | Début |
|---|---|---|
| MYOKARDIA, INC. | Director/Board Member | 17/11/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
